Back to search

Article

VHL Expression Level in the Pathological Tissue is Significantly Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients.

2021-03-19

Abstract excerpt

<h4>Objective: </h4> To investigate the association between expression level of Von Hippel-Lindau(VHL) in pathological tissue and outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. <h4>Methods: </h4>: The pathological samples of NSCLC patients were obtained for immunohistochemical staining to evaluate the expression level of VHL. Furthermore, their clinical data were collected...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c128b7f1-1d84-50b8-b53d-eb880b294a60
DOI
10.21203/rs.3.rs-337079/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
VHL Expression Level in the Pathological Tissue is Significantly Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients.DOI 10.21203/rs.3.rs-337079/v1
VHL Expression Level in the Pathological Tissue is Significantly Associated with Hematotoxicity of Platinum-based Chemotherapy in Non-Small Cell Lung Cancer Patients.Semantic proximity
Applications of Machine Learning to Predict Cisplatin Resistance in Lung CancerSemantic proximity
Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter StudySemantic proximity
First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab？Semantic proximity
Applications of Machine Learning to Predict Cisplatin Resistance in Lung CancerSemantic proximity
DNA damage and repair (DDR) gene mutation profiles in driver gene wild-type advanced non-small cell lung cancer and the predictive role of response to platinum-based chemotherapySemantic proximity
The Prognostic Roles and Clinical Features of CD44v9 in Human Solid Cancers—A Meta-AnalysisSemantic proximity
Strong programmed cell death ligand-1 affect clinical outcomes in advanced non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitorsSemantic proximity
Incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events: a retrospective cohort studySemantic proximity
Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive MutationsSemantic proximity
Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.Semantic proximity
The Correlation Among PD-L1 Expression and the Driver Genes Status in Malignant Pleural Effusion of Lung Adenocarcinoma.Semantic proximity
Select a neighboring publication to make it the new centre.